[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ]
Fırat Tıp Dergisi
2011, Cilt 16, Sayı 4, Sayfa(lar) 206-208
[ Turkish ] [ Tam Metin ] [ PDF ]
Pathological Complete Response After Imatinib Mesylate Therapy in Inoperabl Gastrointestinal Stromal Tumor: A Case Report
Baha ZENGEL1, Ahmet ALACACIOGLU2, Ayse YAGCI3, Hakan POSTACI3, Ozgur KAVAK, Ali Galip, DENECLI1, Erhan GOKMEN
1Bozyaka Research and Training Hospital, 1.General Surgery, Izmir, Turkey
2Bozyaka Research and Training Hospital, Medical Oncology, Izmir, Turkey
3Bozyaka Research and Training Hospital, Pathology, Izmir, Turkey
4Ege University Hospital, Medical Oncology, Izmir, Turkey

Gastrointestinal stromal tumors are characterized by the expression of CD34 and c-kit (CD117) and represent the most common mesenchymal malignancy of the gastrointestinal tract. Imatinib mesylate is small molecule tyrosine kinase inhibitor that suppresses transmembrane receptor c-kit products. Clinical studies for metastatic and inoperabl GISTs have demonstrated partial response rate ranging from 40% to 69% in patients treated with imatinib mesylate. But complete response is rare. We present a 46 year old man patient with unresectable gastrointestinal stromal tumor that has histopatologically proven complete response to imatinib mesylate therapy.

[ Turkish ] [ Tam Metin ] [ PDF ]
[ Ana Sayfa | Editörler | Danışma Kurulu | Dergi Hakkında | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | E-Posta ]